152.65
+5.65(+3.84%)
Currency In USD
| Previous Close | 147 |
| Open | 147.18 |
| Day High | 154.44 |
| Day Low | 147.18 |
| 52-Week High | 154.49 |
| 52-Week Low | 75.56 |
| Volume | 797,702 |
| Average Volume | 505,979 |
| Market Cap | 7.7B |
| PE | -32.69 |
| EPS | -4.67 |
| Moving Average 50 Days | 139.99 |
| Moving Average 200 Days | 118.45 |
| Change | 5.65 |
If you invested $1000 in Axsome Therapeutics, Inc. (AXSM) 10 years ago, it would be worth $16,867.4 as of December 20, 2025 at a share price of $152.65. Whereas If you bought $1000 worth of Axsome Therapeutics, Inc. (AXSM) shares 5 years ago, it would be worth $1,850.98 as of December 20, 2025 at a share price of $152.65.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy
GlobeNewswire Inc.
Nov 06, 2025 12:00 PM GMT
Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA α2,3 receptor positive allosteric modulator Deepens Axsome’s broad and innovative neuroscience portfolio with a synergistic early-stage program for epilepsy NEW YORK, No
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
GlobeNewswire Inc.
Oct 09, 2025 11:00 AM GMT
NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is recognizing Mental Illness Awarene
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
GlobeNewswire Inc.
Oct 07, 2025 11:00 AM GMT
NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for